Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. 01066
01066 logo

01066 Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
5.000
Open
4.960
VWAP
4.94
Vol
6.62M
Mkt Cap
--
Low
4.910
Amount
32.71M
EV/EBITDA(TTM)
5.12
Total Shares
--
EV
2.53B
EV/OCF(TTM)
6.87
P/S(TTM)
1.59

Events Timeline

No data

No data

News

aastocks
4.5
02-26aastocks
HSI Closes Down 384 Points on Futures Settlement Day; Declines in Tech, Auto, Consumer, and Pharma Sectors
  • Hong Kong Stock Market Performance: The Hong Kong stock market opened higher but closed lower, with the HSI down 384 points (1.4%) at 26,381, and total market turnover at HKD259.277 billion.

  • CKI Holdings' Stock Surge: A consortium led by CKI Holdings sold UKPN, resulting in a 4.5% increase in its stock price, while CKH Holdings and Power Assets also saw significant gains.

  • Tech Sector Declines: Alibaba's stock fell 3.6% after a report predicted weak quarterly profits, while other tech stocks like Tencent and Meituan also experienced declines.

  • Pharmaceuticals and Consumer Stocks Drop: Various pharmaceutical and consumer stocks saw significant losses, with declines ranging from 3.3% to 9.2% across multiple companies.

aastocks
6.5
02-06aastocks
G Sachs: This Year, China's Healthcare Sector Depends More on Data and Earnings Clarity; Favorable Outlook for CDMO Companies
  • Healthcare Sector Outlook: Goldman Sachs predicts that the strong trend in China's healthcare sector will continue, with stock trading increasingly focused on companies' execution capabilities and R&D pipelines rather than just licensing expectations.

  • CDMO Companies Favorable: The broker is optimistic about CDMO companies due to their growth potential and reasonable valuations, upgrading WUXI APPTEC and WUXI XDC to Buy.

  • Selective Biotech and Pharma Strategy: Goldman Sachs favors biotech and pharmaceutical companies with promising data releases and transaction expectations, highlighting SKB BIO-B, HENLIUS, and HANSOH PHARMA as favorable investments.

  • Cautious on Medical Services: The broker maintains a neutral stance on the medical devices sector and is cautious about medical services due to cost control measures and weak consumption, downgrading HYGEIA HEALTH and JXR to Neutral/Sell.

aastocks
4.5
01-30aastocks
HSI Drops 580 Points as Commodity Stocks Decline; CSPC Pharma and CKH Holdings Weigh Down Index
  • Hong Kong Stock Market Decline: Hong Kong stocks experienced a significant decline, with the HSI dropping 580 points (2.08%) to close at 27,387, while the HSCEI and HSTECH also fell by 2.5% and 2.1%, respectively, amid a total market turnover of $301.612 billion.

  • Gold and Resource Stocks Performance: Spot gold prices fell over 5%, impacting several gold mining stocks, which tumbled between 10-14%. Resource stocks like Jiangxi Copper and MMG also saw declines of 9-10%, with Jiangxi Copper's short selling ratio reaching 28.3%.

  • Pharmaceutical Sector Developments: CSPC Pharma's stock dropped 10.2% despite a partnership with AstraZeneca for innovative medicines, involving an upfront payment exceeding $9.3 billion. Other pharma stocks also faced declines ranging from 3.3% to 4.9%.

  • Corporate News and Market Rumors: CKH Holdings fell 4.6% following a court ruling on port contracts, while New World Development's share price rose 2.2% amid rumors of a potential change in ownership involving Blackstone.

aastocks
4.5
01-19aastocks
HSI Closes Lower by 281 Points or 1%; Decline in AI and Pharma Stocks, While Power Equipment Stocks Gain
  • Market Performance: The HSI closed down 281 points (1.05%) at 26,563, with total market turnover at HKD225.689 billion. Major tech stocks like Tencent and Meituan also saw declines.

  • Smartphone Shipment Forecasts: Major smartphone manufacturers, including Xiaomi and OPPO, have lowered their annual shipment forecasts, impacting related stocks negatively.

  • Stock Movements: UBTECH Robotics surged 8.6% after a partnership with Airbus, while several other tech and pharmaceutical stocks experienced significant declines, with some dropping over 6%.

  • Economic Indicators: China's unemployment rate remained stable at 5.1% for December, slightly below the forecast of 5.2%, indicating potential weaknesses in domestic demand despite resilient exports.

aastocks
4.5
01-13aastocks
HSI Rises 268 Points at Midday; BABA-W Jumps Over 3%; Pharmaceuticals in Demand
  • Market Performance: The NASDAQ Golden Dragon China Index rose over 4%, with Alibaba ADR leading the charge by climbing 10%, contributing to a strong opening for the Hong Kong bourse, which saw the HSI open 350 points higher and close the morning session up 268 points.

  • Technology Sector Movements: In the technology sector, notable stocks like BABA-W and ALI HEALTH saw gains of 3.5% and 3.3% respectively, while other major players like TENCENT and JD-SW also experienced slight increases, despite some stocks like MEITUAN-W and BIDU-SW declining.

  • Pharmaceutical Sector Highlights: The 44th JPMorgan Healthcare Conference commenced in San Francisco, with several Chinese pharmaceutical companies participating, leading to significant gains for stocks such as REMEGEN, which surged 11.6%, and CSPC PHARMA, which jumped 5.7% after its innovative drug application was accepted.

  • AI Concept Stocks Decline: Several AI concept stocks, including SENSETIME-W and WEIMOB INC, experienced declines ranging from 3.3% to 4.2%, while other stocks like KNOWLEDGE ATLAS and MINIMAX-WP saw even steeper drops of 8.8% and 7.5% respectively.

aastocks
4.5
2025-08-15aastocks
<H Shrs>HSI Ends Down 249 Pts w/ Turnover HKD312.6B; Brokers, Pharmas Charge Against Mkt Trend
  • Market Performance: The HSI closed down 249 points (1%) at 25,220, with increased market turnover of HKD312.687 billion; several major stocks like JD-SW and BABA-W saw significant declines due to disappointing earnings reports.

  • Stock Movements: Notable gains were observed in JD HEALTH (+11.7%) and PA GOODDOCTOR (+8.1%), while other tech and pharma stocks also experienced mixed performances, reflecting varied investor sentiment across sectors.

Wall Street analysts forecast 01066 stock price to rise
0 Analyst Rating
Wall Street analysts forecast 01066 stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
Goldman Sachs
Goldman Sachs
upgrade
AI Analysis
2026-02-06
Reason
Goldman Sachs
Goldman Sachs
Price Target
AI Analysis
2026-02-06
upgrade
Reason
The analyst rating from Goldman Sachs is influenced by several key factors: 1. Continued Growth in Healthcare Sector: The strong trend in China's healthcare sector is expected to persist, indicating a positive outlook for the industry. 2. Focus on R&D Pipelines: Investors are increasingly valuing companies based on their research and development capabilities rather than just licensing transactions, suggesting a shift towards assessing the actual execution capabilities of companies. 3. Importance of Key Data Releases: To achieve returns that outperform the industry, there is a greater reliance on the release of key data, actual transactions, and visibility into earnings realization or turning points. 4. Selective Strategy in Biotech and Pharma: Goldman Sachs is adopting a selective approach, favoring companies with promising early data and significant upcoming data releases. 5. Constructive View on CDMO Companies: The broker has a positive outlook on Contract Development and Manufacturing Organizations (CDMO) due to their accelerated growth and reasonable valuations. 6. Cautious Stance on Medical Services: The broker remains cautious in the medical services sector due to ongoing cost control measures and a weak consumption cycle, leading to downgrades for certain companies in this area. Overall, the ratings reflect a nuanced approach that considers both the potential for growth in specific sub-sectors and the challenges faced by others.

Valuation Metrics

The current forward P/E ratio for (01066.HK) is 9.77, compared to its 5-year average forward P/E of 14.02. For a more detailed relative valuation and DCF analysis to assess 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
14.02
Current PE
9.77
Overvalued PE
19.06
Undervalued PE
8.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
8.81
Current EV/EBITDA
5.14
Overvalued EV/EBITDA
12.30
Undervalued EV/EBITDA
5.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.39
Current PS
1.44
Overvalued PS
3.34
Undervalued PS
1.45

Financials

AI Analysis
Annual
Quarterly

Whales Holding 01066

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is (01066) stock price today?

The current price of 01066 is 4.94 USD — it has decreased -0.8

What is (01066)'s business?

What is the price predicton of 01066 Stock?

Wall Street analysts forecast 01066 stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01066 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is (01066)'s revenue for the last quarter?

revenue for the last quarter amounts to NaN USD, decreased

What is (01066)'s earnings per share (EPS) for the last quarter?

. EPS for the last quarter amounts to USD, decreased

How many employees does (01066). have?

(01066) has 0 emplpoyees as of March 11 2026.

What is (01066) market cap?

Today 01066 has the market capitalization of 0.00 USD.